Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.

Menghrajani, Kamal; Gomez-Arteaga, Alexandra; Madero-Marroquin, Rafael; Zhang, Mei-Jie; Bo-Subait, Khalid; Sanchez, Jonathan; Wang, Hai-Lin; Aljurf, Mahmoud; Assal, Amer; Bacher, Ulrike; Badawy, Sherif M; Bejanyan, Nelli; Bhatt, Vijaya Raj; Bredeson, Christopher N; Byrne, Michael; Castillo, Paul; Cerny, Jan; Chhabra, Saurabh; Ciurea, Stefan Octavian; DeFilipp, Zachariah; ... (2022). Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood advances, 6(3), pp. 828-847. American Society of Hematology 10.1182/bloodadvances.2021004881

Preview	Text advancesadv2021004881.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (1MB) | Preview
	Text Risk_classification_at_diagnosis_predicts_post-HCT_outcomes_in_intermediate-_.pdf - Accepted Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB)

Little is known about whether risk classification at diagnosis predicts post-hematopoietic cell transplantation (HCT) outcomes for acute myeloid leukemia (AML) patients. We evaluated 8709 AML patients from the CIBMTR database and, after selection and manual curation of cytogenetics data, 3779 patients in CR1 were included in the final analysis: 2384 with intermediate-risk, 969 with adverse-risk, and 426 with KMT2A-rearranged disease. An adjusted multivariable analysis compared to intermediate-risk patients detected an increased risk of relapse for KMT2A-rearranged and adverse-risk patients (HR 1.27, p = 0.01 and HR 1.71, p < 0.001, respectively). Leukemia-free survival (LFS) was similar for KMT2A and adverse-risk patients (HR 1.26, p = 0.002 and HR 1.47, p < 0.001), as was overall survival (OS) (HR 1.32, p < 0.001 and HR 1.45, p < 0.001). No differences in outcome could be detected when patients were stratified by KMT2A fusion partner. This is the largest study conducted to date on post-HCT outcomes in AML using manually curated cytogenetics for risk stratification. Our work demonstrates that risk classification at diagnosis remains predictive of post-HCT outcomes in AML. It also highlights the critical need to develop novel treatment strategies for patients with KMT2A rearrangements and adverse-risk disease.

Interest & Impact

Downloads

88 since deposited on 08 Nov 2021
40 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item